Name: 2nd Annual MarketsandMarkets Real-World Evidence and Market Access Conference
Start: 2024-10-14
End: 2024-10-15
Location: Germany, Europe

WHAT TO EXPECT

Updates on European regulatory frameworks governing real-world evidence (RWE) and their impact on market access strategies.
Ensuring the reliability, validity, and relevance of RWE in the context of market access.
Effective collaboration strategies between industry stakeholders and payers to enhance market access outcomes.
Strategies for pricing and reimbursement that align with evidence-based market access approaches.
The impact of patient-reported outcomes on demonstrating product value and effectiveness.
The role of health economics in demonstrating the economic value of healthcare interventions.

Learn about the recent trends and advancements in Real-World Evidence Generation
Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space.
Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators and solution providers

From pharmaceutical and Biopharmaceutical companies

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists within the following departments-

Real-World Evidence
Real-World Data
Data Analytics
Health Economics & Outcomes Research- HEOR
Market Access/Value Access
Policy
Clinical Development & research
Clinical trial
Centre for Observational and Real-World Evidence
Epidemiology
Oncology-RWE
Pricing and Reimbursement
Medical Affairs
Pharmacovigilance
Life Science Analytics
Big data
Data Science
Bio-Statistics
Consumer Healthcare

Other

Payers, Regulators, Research Institutes, and Innovation Centre

CONFERENCE AGENDA

Registration	08:15 - 09:00
Welcome note by MarketsandMarkets	09:00 - 09:05
Opening remarks by the Chairperson	09:05 - 09:10
Data Quality and Standardization
Ensuring the reliability and quality of real-world data used in RCTs.	09:10 - 09:40
Standardization and interoperability challenges in integrating diverse data sources	09:40 - 10:10
Electronic Health Record meets Evidence Ralf Patsch, Head of Real-World Data Business Germany, Cegedim	10:10 - 10:40
Morning Refreshments and Poster Presentation \| One-to-One Networking Meeting	10:40 - 11:30
RWE for Health Technology Assessment (HTA)
Role of RWE in supporting HTA submissions	11:30 - 12:00
Addressing methodological challenges in RWE-based HTAs	12:00 - 12:30
Addressing methodological challenges in RWE-based HTAs	12:30 - 13:00
Lunch and Poster Presentation \| One-to-One Networking	13:00 - 14:00
Post-Marketing Surveillance and Phase IV Trials
Leveraging real-world evidence for post-approval monitoring.	14:00 - 14:30
Sponsor Presentation – Slot Reserved for Silver/Bronze Sponsors	14:30 - 15:00
Panel Discussion- RWE in assessing long-term safety and effectiveness of interventions.	15:00 - 15:40
Evening Refreshments and Poster Presentation \| One-to-One Networking	15:40 - 16:25
Patient Recruitment and Retention
Strategies for recruiting and retaining diverse patient populations	16:25 - 16:55
Closing remarks by the Chair Chairperson.	16:55 - 17:25
Drinks Reception and Networking .....END OF DAY 1.....	17:25 - 17:50

Registration	08:15 - 08:50
Welcome note by MarketsandMarkets	08:50 - 09:05
Opening remarks by the Chairperson	09:05 - 09:10
Patient-Centric Market Access
Utilizing patient-reported outcomes (PROs) and patient-centric RWE	09:10 - 09:40
Sponsor Presentation – Slot Reserved for Gold / Silver Sponsors	09:40 - 10:10
Engaging patients in the market access process	10:10 - 10:45
Morning Refreshments and Poster Presentation \| One-to-One Networking	10:45 - 11:30
RWE in Market Access for Rare Diseases
Unique challenges and opportunities in demonstrating value for rare disease treatments	11:30 - 12:40
Sponsor Presentation – Slot Reserved for Bronze Sponsors	12:40 - 13:00
Navigating pricing and reimbursement considerations for orphan drugs	13:00 - 13:30
Closing remarks by the chairperson	13:30 - 13:35
Lunch and Poster Presentation \| One-to-One Networking	13:35 - 13:35
END OF CONFERENCE
...........	13:35 - 13:35